Can Steroids Induce Atrial Flutter?
Yes, systemic corticosteroids can induce atrial flutter and atrial fibrillation, with the risk being dose-dependent and highest during active treatment, particularly with high-dose therapy (≥7.5 mg prednisone equivalents daily). 1
Evidence Strength and Risk Magnitude
The 2024 guideline evidence demonstrates that corticosteroids increase the risk of atrial fibrillation/flutter with a relative risk of 2.49 (95% CI 1.56-3.97), particularly in patients with respiratory diseases where the risk jumps to 3.67 (95% CI 1.96-6.88) 1. A comprehensive 2026 meta-analysis of 23 studies involving 679,330 individuals confirmed that exogenous steroids elevate the risk of atrial fibrillation by 1.74 times (95% CI 1.55-1.96) 2.
Route-Specific Risk Profile
The risk varies significantly by administration route 2:
- Intravenous corticosteroids: 2.02-fold increased risk
- Oral corticosteroids: 1.95-fold increased risk
- Inhaled corticosteroids: 1.67-fold increased risk (lowest risk)
Critical Dose and Timing Considerations
High-dose exposure (≥7.5 mg prednisone equivalents) carries a 6.07-fold increased risk (95% CI 3.90-9.42), while low-to-intermediate doses show minimal association (OR 1.42,95% CI 0.72-2.82) 3.
The temporal pattern is crucial:
- New users face the highest risk: OR 3.62 (95% CI 3.11-4.22) 4
- Current users within 60 days: OR 1.92 (95% CI 1.79-2.06) 4
- Former users show no increased risk: OR 1.00 (95% CI 0.96-1.06) 4
This indicates the arrhythmogenic effect is reversible upon discontinuation 1.
Underlying Mechanisms
Corticosteroids trigger atrial flutter/fibrillation through multiple pathways 1:
- Direct electrophysiologic effects: Increased cellular K+ efflux shortens atrial action potential duration (AAPD) and effective refractory period (AERP)
- Volume overload: Mineralocorticoid-like effects increase plasma volume, elevating atrial pressures and causing atrial enlargement
- Chronic cardiovascular remodeling: Long-term use promotes atherosclerosis, diabetes, hypertension, and heart failure—all independent AF risk factors
- Cardiomyocyte changes: Mechanical and electrical remodeling, cellular senescence, and cardiac hypertrophy 2
Clinical Context Independence
The association persists regardless of underlying indication 3. The risk remains elevated in:
- Patients with asthma/COPD: OR 4.02 (95% CI 2.07-7.81)
- Patients with rheumatic, allergic, or hematologic diseases: OR 7.90 (95% CI 4.47-13.98)
- Patients with and without pre-existing cardiovascular disease
Important Caveats
Inhaled steroids carry minimal risk and are not associated with increased arrhythmias in short-term use 1. The risk calculation must account for inflammation as a confounding factor 2, since the underlying inflammatory conditions requiring steroids may independently increase AF risk.
Monitor patients receiving high-dose systemic corticosteroids closely for new-onset atrial arrhythmias, especially during the first weeks of therapy. Consider dose reduction or alternative therapies when feasible in patients with pre-existing AF risk factors.